NCT06155422View on ClinicalTrials.gov

A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

Not yet recruitingOBSERVATIONAL

Enrollment

670

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions

Recurrent or Metastatic Cervical Cancer

Interventions

DRUG

Cadonilimab

recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment

All Listed Sponsors

lead

Gang Chen (101199)

OTHER

NCT06155422 - A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer | Biotech Hunter | Biotech Hunter